A commonly cited industry estimate is that monitoring and related activities account for a substantial portion of clinical trial budgets. RBQM and centralized monitoring approaches have been associated in the literature and industry analyses with sizable reductions in monitoring effort and cost in many programs, especially when combined with validated automation and eSource capture. Nevertheless, the precise savings will vary by study size, phase, and therapeutic area; therefore, sponsors should use study-specific modeling rather than rely on a single percent reduction figure.